Earnings Update: Sinopharm Group Co. Ltd. (HKG:1099) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Last week, you might have seen that Sinopharm Group Co. Ltd. (HKG:1099) released its annual result to the market. The early response was not positive, with shares down 2.2% to HK$19.96 in the past wee
SINOPHARM GROUP CO. LTD. To Go Ex-Dividend On June 17th, 2024 With 0.12623 USD Dividend Per Share
March 26th - $SINOPHARM GROUP CO. LTD.(SHTDF.US)$ is trading ex-dividend on June 17th, 2024. Shareholders of record on June 18th, 2024 will receive 0.12623 USD dividend per share on August 13th, 2
Guojin Securities: Innovative drugs are an important field for the implementation of scientific and technological progress. Overall, performance will rise simultaneously with market performance
Guojin Securities released a research report saying that global innovative drugs are an important field for realizing scientific and technological progress, and China's innovative drug industry chain is on the rise. With the full restoration of in-hospital diagnosis and treatment, the introduction of national incentives and support policies for innovative drugs one after another, and the pace of internationalization of Chinese pharmaceutical companies, the industry as a whole will usher in simultaneous improvements in performance and market performance. It is recommended to invest in two types of targets: 1) choose a racetrack, preferring domestic targets mapped by metabolic, neurological, and self-immune indications and cutting-edge innovators in overseas breakthroughs; 2) select leaders, which are optimistic about bottom-up and internationalization breakthroughs. Recommended attention: Cinda Biotech (01801), Kangfang Biology
Sinopharm Group Co. Ltd.'s (HKG:1099) Stock Is Going Strong: Is the Market Following Fundamentals?
Sinopharm Group (HKG:1099) has had a great run on the share market with its stock up by a significant 17% over the last three months. Given that the market rewards strong financials in the long-term
Sinopharm Group Co. Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 53% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Sinopharm Group fair value estimate is HK$31.57 Sinopharm Group's HK$20.70 share price signals that it might be 34% undervalued Analyst pr
Investors Don't See Light At End Of Sinopharm Group Co. Ltd.'s (HKG:1099) Tunnel
When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 10x, you may consider Sinopharm Group Co. Ltd. (HKG:1099) as an attractive investment with its 6.7x P/E r
Weekend news: The aircraft hatch fell off in the air! After multiple airlines grounded Boeing airliners and US stocks generally fell, the Big Seven evaporated 3 trillion dollars to determine the direction of the 2024 market
For more global financial information, please go to 7×24 real-time financial news, last week's market review and closing: the three major US stock indexes all recorded declines this week, ending a record of nine consecutive weeks of rising, January 5: Apple faced antitrust lawsuits from the US Department of Justice. The stock price fell for 5 days in a row, popular Chinese securities generally fell by more than 5%, and Bilibili and NetEase fell more than 4%. New York gold futures were basically flat on Friday, falling less than 1% this week, and US WTI crude oil closed more than 2.2% higher this week European stocks collectively fell Europe The Stoxx 50 Index fell 0
Why Sinopharm Group Co. Ltd. (HKG:1099) Could Be Worth Watching
Sinopharm Group Co. Ltd. (HKG:1099), might not be a large cap stock, but it received a lot of attention from a substantial price movement on the SEHK over the last few months, increasing to HK$22
Institutions Own 26% of Sinopharm Group Co. Ltd. (HKG:1099) Shares but Private Companies Control 57% of the Company
Key Insights Sinopharm Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The largest shareholder of the company is
CICC: Maintaining Heyo-B's “Outperform Industry” rating, target price of HK$6.76
CICC released a research report stating that it maintains Heyo-B (02256) “outperforms the industry” rating, and the target price for 2023 remains unchanged at HK$6.76 in its profit forecast. The company recently announced a number of developments in products such as ABSK021 (CSF-1R inhibitor), including active clinical data updates for TGCT at the CTOS annual meeting, initiation of phase II clinical administration for pancreatic cancer, and more clinical progress of early pipeline molecules. CICC's main views are as follows: ABSK021 was used for the TGCT phase Ib data update, and the response rate was further improved. According to the company's official website, A
An Intrinsic Calculation For Sinopharm Group Co. Ltd. (HKG:1099) Suggests It's 26% Undervalued
Key Insights The projected fair value for Sinopharm Group is HK$26.57 based on 2 Stage Free Cash Flow to Equity Current share price of HK$19.60 suggests Sinopharm Group is potentially 26% undervalue
Direct access to the Expo | Ailang China signs strategic cooperation agreement with Sinopharm Shanghai
On November 6, Ailang China and Sinopharm Group Shanghai Medical Devices Co., Ltd. (hereinafter referred to as “Sinopharm Shanghai Company”) signed a memorandum of strategic cooperation at the 6th Expo to establish a strategic cooperative relationship in the field of products and services, and cooperate in various areas such as hospital logistics supply, process management and logistics distribution, thus improving the overall quality of life of patients. Shi Hua, global vice president of Ailang Medical and general manager of China, said that Alang Medical has long focused on interventional medicine, and its products mainly cover three areas: tumor intervention, vascular intervention, and nursing intervention. The two sides signed a strategic cooperation agreement here today, which will go deeper into the future
Is There Now An Opportunity In Sinopharm Group Co. Ltd. (HKG:1099)?
Sinopharm Group Co. Ltd. (HKG:1099), is not the largest company out there, but it saw significant share price movement during recent months on the SEHK, rising to highs of HK$26.90 and falling to
Private Companies Account for 57% of Sinopharm Group Co. Ltd.'s (HKG:1099) Ownership, While Institutions Account for 25%
Key Insights Sinopharm Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 57% of the company is held by a single sh
Sinopharm Group Co. Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 23% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Sinopharm Group fair value estimate is HK$17.98 Current share price of HK$23.45 suggests Sinopharm Group is potentially 30% overvalued Ana
Is Weakness In Sinopharm Group Co. Ltd. (HKG:1099) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Sinopharm Group's (HKG:1099) recent performance, when its stock has declined 4.3% over the past month. However, a closer look at its sound financials might
Both Private Companies Who Control a Good Portion of Sinopharm Group Co. Ltd. (HKG:1099) Along With Institutions Must Be Dismayed After Last Week's 4.1% Decrease
Key Insights Significant control over Sinopharm Group by private companies implies that the general public has more power to influence management and governance-related decisions China National Phar
WHO Chief Expects COVID Emergency to End This Year
Sinopharm Group Co. Ltd.'s (HKG:1099) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sinopharm Group (HKG:1099) has had a great run on the share market with its stock up by a significant 16% over the last three months. Given that the market rewards strong financials in the long-term
Sinopharm Group Co. Ltd. (HKG:1099) Most Popular Amongst Private Companies Who Own 57% of the Shares, Institutions Hold 23%
Key Insights Sinopharm Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 57% of the company is held by a single sh
No Data